The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the Covid-19 pandemic.

AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.

Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.

U.S. President Donald Trump’s administration tapped National Cancer Institute Director Norman Sharpless to serve as acting commissioner for the Food and Drug Administration.

AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.

The U.S. FDA granted approval for expanded use of AstraZeneca‘s immunotherapy drug Imfinzi to treat non-small cell lung cancer whose tumors can not be surgically removed.

Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

The U.S. Food and Drug Administration approved Pfizer Inc.’s drug Mylotarg for certain patients with acute myeloid leukemia (AML), re-clearing a drug that had been pulled off the market in 2010.

A U.S. Food and Drug Administration advisory panel unanimously recommended approval of Novartis AG’s CAR-T therapeutic, CTL019 (tisagenlecleucel), for B-cell acute lymphoblastic leukemia.

The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines.